Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Cut to $755.00 by Analysts at Morgan Stanley

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) had its target price lowered by analysts at Morgan Stanley from $958.00 to $755.00 in a research note issued to investors on Monday,Benzinga reports. The firm currently has an "overweight" rating on the biopharmaceutical company's stock. Morgan Stanley's price objective would indicate a potential upside of 56.18% from the company's current price.

Several other brokerages have also recently commented on REGN. Wells Fargo & Company cut shares of Regeneron Pharmaceuticals from an "overweight" rating to an "equal weight" rating and reduced their price objective for the company from $700.00 to $580.00 in a research note on Friday, May 30th. Citigroup upgraded shares of Regeneron Pharmaceuticals from a "neutral" rating to a "buy" rating and boosted their price objective for the company from $600.00 to $700.00 in a research report on Wednesday, May 14th. Leerink Partners upgraded shares of Regeneron Pharmaceuticals from a "market perform" rating to an "outperform" rating and boosted their price target for the company from $762.00 to $834.00 in a research report on Wednesday, February 5th. Wall Street Zen cut shares of Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Thursday, May 1st. Finally, JPMorgan Chase & Co. dropped their target price on shares of Regeneron Pharmaceuticals from $1,100.00 to $1,000.00 and set an "overweight" rating on the stock in a research note on Monday, March 31st. One research analyst has rated the stock with a sell rating, six have assigned a hold rating, seventeen have issued a buy rating and three have given a strong buy rating to the stock. According to MarketBeat, Regeneron Pharmaceuticals presently has a consensus rating of "Moderate Buy" and a consensus target price of $844.48.

Regeneron Pharmaceuticals Stock Performance

NASDAQ REGN traded down $1.51 during trading on Monday, reaching $483.43. The company's stock had a trading volume of 1,056,486 shares, compared to its average volume of 1,143,519. The company has a current ratio of 4.73, a quick ratio of 3.95 and a debt-to-equity ratio of 0.09. The firm has a market capitalization of $52.19 billion, a price-to-earnings ratio of 12.63, a price-to-earnings-growth ratio of 2.34 and a beta of 0.43. Regeneron Pharmaceuticals has a 12 month low of $476.49 and a 12 month high of $1,211.20. The firm has a 50 day moving average price of $575.25 and a 200 day moving average price of $661.35.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share for the quarter, missing the consensus estimate of $8.83 by ($0.61). The firm had revenue of $3.03 billion for the quarter, compared to analyst estimates of $3.40 billion. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The company's quarterly revenue was down 3.7% compared to the same quarter last year. During the same quarter last year, the company earned $9.55 earnings per share. As a group, equities analysts anticipate that Regeneron Pharmaceuticals will post 35.92 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Capital International Investors raised its position in shares of Regeneron Pharmaceuticals by 41.6% in the 4th quarter. Capital International Investors now owns 4,736,929 shares of the biopharmaceutical company's stock valued at $3,373,859,000 after acquiring an additional 1,390,534 shares during the period. Norges Bank bought a new position in shares of Regeneron Pharmaceuticals in the fourth quarter valued at $802,036,000. GAMMA Investing LLC grew its stake in shares of Regeneron Pharmaceuticals by 89,825.0% in the first quarter. GAMMA Investing LLC now owns 815,620 shares of the biopharmaceutical company's stock valued at $517,291,000 after buying an additional 814,713 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its position in Regeneron Pharmaceuticals by 63.5% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 2,085,447 shares of the biopharmaceutical company's stock worth $1,485,527,000 after purchasing an additional 810,144 shares during the period. Finally, Nuveen LLC bought a new position in Regeneron Pharmaceuticals during the first quarter worth $343,764,000. Institutional investors and hedge funds own 83.31% of the company's stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.